Veru anticipates FDA feedback on its regulatory pathway after the QUALITY study showed positive efficacy and safety data.
2 reports, 1 independent
Updated Aug 12
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Veru anticipates FDA feedback on its regulatory pathway after the QUALITY study showed positive efficacy and safety data.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- FDA approval enables commercial opportunity involving CBRE Group.
- The FDA is reviewing drug data and company resubmissions, while also overseeing the functions of the U.S. Department of Health and Human Services.
- Industry trends are influenced by regulatory body requests, according to a recent report involving RTI International.
- FDA and Pfizer are seeking regulatory approval for their products.
- The FDA is accused of failing to enforce safety regulations and operating under current rules without in-person oversight.
Coverage
Newest first; wire copies grouped- GlobeNewswireVeru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress --Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to sema
- GlobeNewswireVeru to Participate in the 2025 BTIG Virtual Biotech Conference MIAMI, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on devel